Cover Image
市場調查報告書

細胞週期蛋白依賴型激酶4:開發中產品分析

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 367821
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
細胞週期蛋白依賴型激酶4:開發中產品分析 Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 102 Pages
簡介

本報告提供以細胞週期蛋白依賴型激酶4為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

細胞週期蛋白依賴型激酶4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Beta Pharma, Inc.
  • Eli Lilly and Company
  • G1 Therapeutics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Novartis AG
  • Onconova Therapeutics, Inc.
  • Pfizer Inc.
  • Presage Biosciences, Inc.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • TEIJIN FIBERS製藥
  • Theryte Limited
  • Tiziana Life Sciences Plc
  • Vichem Chemie Research Ltd.
  • ViroStatics srl

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0394TDB

Summary

Global Markets Direct's, 'Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016', provides in depth analysis on Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Overview
    • Therapeutics Development
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Products under Development by Stage of Development
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Products under Development by Therapy Area
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Products under Development by Indication
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Products under Development by Companies
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
    • Beta Pharma, Inc.
    • Eli Lilly and Company
    • G1 Therapeutics, Inc.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Novartis AG
    • Onconova Therapeutics, Inc.
    • Pfizer Inc.
    • Presage Biosciences, Inc.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Teijin Pharma Limited
    • Theryte Limited
    • Tiziana Life Sciences Plc
    • Vichem Chemie Research Ltd.
    • ViroStatics srl
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
    • abemaciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPI-1178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-1748 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FLX-925 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-1T28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-1T38 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GZ-381 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • milciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMD-37K - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ON-123300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ribociclib succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHR-6390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THR-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • voruciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Projects
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Featured News & Press Releases
    • Jul 06, 2016: Study Tests New Breast Cancer Drug In African American Women
    • Jun 03, 2016: Presage Biosciences Appoints David Johnson to Board of Directors
    • Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy
    • May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data
    • May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types
    • May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO
    • May 18, 2016: MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer
    • May 10, 2016: Health Canada approves new first-line treatment for women living with metastatic breast cancer
    • Apr 20, 2016: Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting
    • Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer
    • Apr 19, 2016: Pfizer Announces Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib)
    • Apr 15, 2016: G1 Therapeutics to Present Preliminary clinical data on CDK4/6 Inhibitor G1T28 at the 2016 American Association for Cancer Research Annual Meeting
    • Apr 15, 2016: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor G1T38 at the 2016 American Association for Cancer Research Annual Meeting
    • Mar 14, 2016: New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows
    • Mar 07, 2016: New therapeutic target in myeloma discovered
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Beta Pharma, Inc., H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by G1 Therapeutics, Inc., H2 2016
  • Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by Onconova Therapeutics, Inc., H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Pipeline by Presage Biosciences, Inc., H2 2016
  • Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2016
  • Pipeline by Teijin Pharma Limited, H2 2016
  • Pipeline by Theryte Limited, H2 2016
  • Pipeline by Tiziana Life Sciences Plc, H2 2016
  • Pipeline by Vichem Chemie Research Ltd., H2 2016
  • Pipeline by ViroStatics srl, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top